Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).
Kitazawa T, Seino H, Ohashi H, Inazawa T, Inoue M, Ai M, Fujishiro M, Kuroda H, Yamada M, Anai M, Ishihara H. Kitazawa T, et al. Among authors: seino h. Diabetes Obes Metab. 2020 Sep;22(9):1659-1663. doi: 10.1111/dom.14059. Epub 2020 May 7. Diabetes Obes Metab. 2020. PMID: 32314464 Free PMC article. Clinical Trial.
Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study.
Sone H, Tanaka S, Tanaka S, Iimuro S, Ishibashi S, Oikawa S, Shimano H, Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group. Sone H, et al. Diabetes Care. 2012 May;35(5):1150-7. doi: 10.2337/dc11-1412. Epub 2012 Feb 14. Diabetes Care. 2012. PMID: 22338107 Free PMC article.
Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.
Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, Niemeyer M, Seino H; BEGIN BB T1 Study Group. Davies MJ, et al. Among authors: seino h. Diabetes Obes Metab. 2014 Oct;16(10):922-30. doi: 10.1111/dom.12298. Epub 2014 May 8. Diabetes Obes Metab. 2014. PMID: 24702700 Free PMC article. Clinical Trial.
Effects of linagliptin vs. voglibose on daily glucose excursions during continuous glucose monitoring of Japanese type 2 diabetes patients (L-CGM): A randomized, open-label, two-arm, parallel comparative trial.
Satoh H, Ohira T, Moriya C, Inoue I, Kuribayashi S, Seino H, Hirai H, Hiyoshi T, Watada H; L-CGM Study Group. Satoh H, et al. Among authors: seino h. Diabetes Metab. 2017 Dec;43(6):550-553. doi: 10.1016/j.diabet.2017.07.010. Epub 2017 Sep 22. Diabetes Metab. 2017. PMID: 28947255 Clinical Trial. No abstract available.
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Mathieu C, Dandona P, Gillard P, Senior P, Hasslacher C, Araki E, Lind M, Bain SC, Jabbour S, Arya N, Hansen L, Thorén F, Langkilde AM; DEPICT-2 Investigators. Mathieu C, et al. Diabetes Care. 2018 Sep;41(9):1938-1946. doi: 10.2337/dc18-0623. Epub 2018 Jul 19. Diabetes Care. 2018. PMID: 30026335 Free article. Clinical Trial.
Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy.
Ishihara H, Anai M, Seino H, Kitazawa T, Ohashi H, Ai M, Inoue M, Fujishiro M, Inazawa T, Kuroda H, Yamada M. Ishihara H, et al. Among authors: seino h. Diabetes Ther. 2018 Oct;9(5):2117-2125. doi: 10.1007/s13300-018-0491-4. Epub 2018 Aug 25. Diabetes Ther. 2018. PMID: 30145651 Free PMC article.
Benefit of Early Add-on of Linagliptin to Insulin in Japanese Patients With Type 2 Diabetes Mellitus: Randomized-Controlled Open-Label Trial (TRUST2).
Katsuno T, Shiraiwa T, Iwasaki S, Park H, Watanabe N, Kaneko S, Terasaki J, Hanafusa T, Imagawa A, Shimomura I, Ikegami H, Koyama H, Namba M, Miyagawa JI; TRUST2 study group. Katsuno T, et al. Adv Ther. 2021 Mar;38(3):1514-1535. doi: 10.1007/s12325-021-01631-y. Epub 2021 Jan 28. Adv Ther. 2021. PMID: 33507500 Clinical Trial.
187 results